Russia registers sharp growth of insulin demand and sales

The demand for insulin in Russia is steadily growing, which provides some opportunities for global majors operating in this market segment, reports The Pharma Letter’s local correspondent.

According to various Russian media reports, insulin sales in the country’s pharmaceutical retail since the beginning of the current year have grown by an average of three-four-fold, with the growth ongoing.

According to analysts at Chestny Znak, Russa’s single labeling operator, insulin sales in Russia for the three quarters of 2022 amounted to 7.6 million packs, which is 55% higher than for the same period last year. Chestny Znak believes that increased demand will not lead to shortages of insulin in the Russian market, while its local stocks will last for nine months.